In a patient on tirzepatide 15 mg weekly, metformin 2000 mg daily, and 28 units of long‑acting insulin most days, how should the basal insulin be adjusted to minimize hypoglycemia?

Basal Insulin Adjustment with Tirzepatide

In a patient on tirzepatide 15 mg weekly with metformin and basal insulin, reduce the basal insulin dose by approximately 20-25% (from 28 units to approximately 21-22 units) immediately to minimize hypoglycemia risk, with further titration based on glucose monitoring.

Rationale for Insulin Reduction

The 2025 ADA Standards of Care provide clear guidance: when hypoglycemia occurs without a clear reason, lower the insulin dose by 10-20% 1. However, this reactive approach may be insufficient when initiating or maintaining tirzepatide alongside basal insulin.

Recent clinical evidence demonstrates that tirzepatide significantly reduces insulin requirements:

• Real-world data shows patients transitioning from GLP-1 RAs to tirzepatide experienced a median 9.2% reduction in insulin dose, with those having baseline A1C ≤8.0% requiring even larger reductions (-22.6%) 2
• SURPASS trials (pooled analysis) demonstrated significant reductions in basal insulin glargine doses when tirzepatide was added, regardless of baseline insulin dose, age, or diabetes duration 3
• Type 1 diabetes data (though off-label) showed 25% total daily insulin reduction was appropriate at tirzepatide initiation in well-controlled patients 4

Specific Dosing Algorithm

Immediate Action:

• Reduce basal insulin from 28 units to 21-22 units (approximately 20-25% reduction)
• This is more aggressive than the standard 10-20% reduction because:
  • Patient is on maximum tirzepatide dose (15 mg weekly)
  • Already on metformin 2000 mg (maximal dose)
  • Triple therapy increases hypoglycemia risk 5

Monitoring and Titration:

• Check fasting plasma glucose daily for the first 2 weeks
• Target fasting glucose per individualized goals (see ADA Section 6) 1
• If fasting glucose remains elevated (>130 mg/dL consistently), increase basal insulin by 2 units every 3 days 1
• If hypoglycemia occurs (glucose <70 mg/dL), reduce by an additional 10-20% 1

Critical Safety Considerations

Hypoglycemia Risk Factors:

The combination of tirzepatide, metformin, and insulin creates additive hypoglycemia risk 5. The FDA label explicitly warns that metformin combined with insulin requires lower insulin doses 5.

Key warning from case reports: One patient developed severe DKA after reducing basal insulin from 40 to 20 units due to fear of hypoglycemia following tirzepatide initiation 6. This highlights:

• Never discontinue basal insulin completely
• Maintain sick-day rules (continue basal insulin during illness/poor oral intake)
• The 20-25% reduction is appropriate, but complete cessation is dangerous

Baseline A1C Matters:

If this patient's baseline A1C is ≤8.0%, they will likely need more aggressive insulin reduction (potentially 30-40% reduction) based on real-world evidence 2. Conversely, if A1C >8.5%, the standard 20-25% reduction is appropriate 3.

Ongoing Management

Signs of Overbasalization to Monitor:

• Large bedtime-to-morning glucose differential
• Postprandial-to-preprandial glucose differential
• Hypoglycemia (aware or unaware)
• High glucose variability 1

When to Consider Further Adjustments:

If A1C remains above goal after 3-6 months despite optimized basal insulin:

• Do not simply increase basal insulin further if signs of overbasalization exist
• Consider adding prandial insulin (start 4 units with largest meal or 10% of basal dose) 1
• However, with tirzepatide 15 mg already providing substantial postprandial glucose control, prandial insulin may not be necessary

Common Pitfalls to Avoid

1. Failing to reduce insulin proactively: Waiting for hypoglycemia to occur before reducing insulin is reactive and dangerous
2. Inadequate monitoring: Daily fasting glucose checks are essential during the first 2-4 weeks
3. Stopping basal insulin entirely: Even with maximal tirzepatide, basal insulin provides essential coverage 6
4. Ignoring gastrointestinal symptoms: Tirzepatide's GI effects may reduce oral intake, temporarily requiring further insulin reduction 6

Prescribe glucagon for emergency hypoglycemia as recommended when using basal insulin 1.